Adherex Technologies has signed a license agreement with the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, for the exclusive use of data from a Phase III trial conducted by Charlotte Zuur and her colleagues with sodium thiosulfate to prevent hearing loss in adults with head and neck cancer.

Adherex Technologies has received FDA orphan drug designation for ADH-1 in conjunction with melphalan for the treatment of stage IIB/C, III, and IV malignant melanoma.

Adherex Technologies has completed patient enrollment in the Phase I portion of the clinical trial of systemic ADH-1, in combination with isolated limb infusion melphalan and is proceeding with a multi-institutional Phase IIb expansion of the melanoma study.

Adherex Technologies and its collaborative partner, the International Childhood Liver Tumour Strategy Group, have begun a UK-based Phase III trial of sodium thiosulfate to prevent hearing loss in children with liver cancer.

Adherex Technologies and the US Oncology Research network has initiated a phase I trial of the cancer drug ADH-1 in combination with chemotherapy.